Imipenem/Cilastatin Hikma Farmacêutica Portugal

Imipenem, the active ingredient in Imipenem/Cilastatin Hikma Farmacêutica Portugal, is a carbapenem presented as a powder for solution for injection for intravenous use. It treats severe bacterial infections, including complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft‑tissue infections, nosocomial pneumonia, and septicemia, primarily in hospitalized adult patients.

GNH USA supplies Imipenem/Cilastatin Hikma Farmacêutica Portugal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU GMP standards and provides reliable cold‑chain logistics to ensure product integrity across global markets.

Imipenem/Cilastatin is a broad‑spectrum carbapenem antibiotic indicated for serious infections affecting various organ systems.

- Complicated intra‑abdominal infections: achieves bacterial eradication in the peritoneal cavity and associated tissues. - Complicated urinary tract infections: provides effective coverage of Gram‑negative and Gram‑positive pathogens in the urinary system. - Skin and soft‑tissue infections: eliminates resistant bacteria in deep or extensive dermal lesions. - Nosocomial pneumonia: treats hospital‑acquired lung infections caused by multidrug‑resistant organisms. - Septicemia: rapidly clears bloodstream infections in critically ill patients.

Imipenem/Cilastatin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: may be watery and self‑limiting. - Headache: transient cranial pain. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in transaminases. - Injection site pain: local discomfort after administration.

Serious or Rare Side Effects: - Seizures: particularly in patients with renal impairment or high doses. - Anaphylaxis: acute, potentially life‑threatening hypersensitivity reaction. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth. - Renal toxicity: acute kidney injury in susceptible individuals.

Prior to initiating Imipenem/Cilastatin therapy, several safety considerations should be evaluated. - Renal function: assess creatinine clearance and adjust dose in impairment. - History of seizures: avoid or use with caution in patients with CNS disorders. - Hypersensitivity: confirm no allergy to β‑lactams or carbapenems. - Concomitant valproic acid: discontinue or replace, as carbapenems reduce valproate levels. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/Cilastatin can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: carbapenems markedly decrease serum valproate concentrations, risking seizure breakthrough. - Probenecid: may increase imipenem plasma levels, heightening neurotoxicity risk. - High‑dose aminoglycosides: combined nephrotoxic potential can exacerbate renal injury.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance renal clearance, requiring dose reassessment. - Oral contraceptives: potential reduction in hormonal efficacy, advise backup contraception. - NSAIDs: may increase risk of renal impairment when used together.